We report 2 cases of apixaban use as prophylaxis against thromboembolism in the
nephrotic syndrome (NS), and review the existing literature on direct-acting oral …

Background Nephrotic syndrome (NS) is associated with an increased risk of
thromboembolic events (TEs), due to hemostatic derangements. The use of direct oral …

Background Nephrotic syndrome (NS) is associated with increased risk of thromboembolic
events (TE) adding to the morbidity and mortality. International guidelines recommend …

Background: Evidence supporting venous thromboembolism (VTE) prophylaxis with direct
oral anticoagulants (DOACs) in patients with nephrotic syndrome (NS) is limited to case …

Background The use of direct oral anticoagulants (DOACs) is restricted by the limitations of
clinical trials guiding therapy for patients with renal impairment, as many of these trials …

Objective: Hypercoagulability, resulting in thromboembolic events, can be a life-threatening
complication of nephrotic syndrome (NS). Conventional anticoagulants, such as warfarin …

Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD
to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are …

Anticoagulation in patients with impaired kidney function can be challenging since drugs'
pharmacokinetics and bioavailability are altered in this setting. Patients with chronic kidney …

Direct oral anticoagulants in chronic kidney disease: an upd... : Current Opinion in Nephrology
and Hypertension Direct oral anticoagulants in chronic kidney disease: an update : Current …

Objective: To evaluate how treatment with DOACs for VTE affects thrombosis and bleeding
outcomes compared to warfarin in CKD and dialysis patients. Data Sources: A literature …